| Novel therapeutic agents under investigation for malignant melanoma. | |
| | |
MedLine Citation:
|
PMID: 12943498 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Malignant melanoma presents a therapeutic challenge. Patients at high risk for recurrence (stage III) are eligible for adjuvant treatment with IFN-alpha or may enrol in a clinical trial. Both options offer no meaningful survival advantage. Patients with metastatic disease (stage IV) have a 5-year survival of < 10% and have no effective treatment options. Despite aggressive investigations into vaccine therapy, no vaccine has yet received FDA approval. Biological therapies with IFN-alpha and IL-2 have demonstrated a real but minimal effect. Chemotherapeutic options are even more dismal. Single-agent chemotherapy yields a 15-20% response rate of short lived duration. Combination chemotherapy alone or with immunological adjuvants yields response rates of 35-45% but with significant toxicity and no significant improvement in survival. Novel treatment agents that target metabolic pathways, angiogenesis inhibitors, antisense therapies, gene therapies and innovative vaccines may offer hope for an otherwise grave disease. |
| | |
Authors:
|
Anna C Pavlick; Sylvia Adams; Matthew A Fink; Amanda Bailes |
Related Documents
:
|
8180388 - Increased incidence of second neoplasms in patients treated with interferon alpha 2b fo... 10915728 - Interferon beta prevents recurrence of hepatocellular carcinoma after complete resectio... 2222898 - Subcutaneous interleukin-2 and interferon-alpha 2b in patients with metastatic renal ce... 21078048 - Oncological outcomes after laparoscopic and open radical nephroureterectomy: results fr... 23412768 - The role of para-aortic lymphadenectomy in endometrial cancer. 8180388 - Increased incidence of second neoplasms in patients treated with interferon alpha 2b fo... |
Publication Detail:
|
Type: Journal Article; Research Support, U.S. Gov't, P.H.S.; Review |
Journal Detail:
|
Title: Expert opinion on investigational drugs Volume: 12 ISSN: 1354-3784 ISO Abbreviation: Expert Opin Investig Drugs Publication Date: 2003 Sep |
Date Detail:
|
Created Date: 2003-08-28 Completed Date: 2004-01-06 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9434197 Medline TA: Expert Opin Investig Drugs Country: England |
Other Details:
|
Languages: eng Pagination: 1545-58 Citation Subset: IM |
Affiliation:
|
New York University Cancer Institute, 462 First Avenue, BCD 556, New York, NY, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adjuvants, Immunologic
/
therapeutic use Angiogenesis Inhibitors / therapeutic use Antibodies, Monoclonal / therapeutic use Antineoplastic Agents / therapeutic use Cancer Vaccines / therapeutic use Chemotherapy, Adjuvant Clinical Trials as Topic Cytokines / metabolism Enzyme Inhibitors / therapeutic use Gene Therapy Humans Immunotherapy Melanoma / drug therapy, secondary, therapy* Neoplasm Metastasis Oligonucleotides, Antisense / therapeutic use |
| Grant Support | |
ID/Acronym/Agency:
|
T32-CA16087/CA/NCI NIH HHS; T32-HL07151/HL/NHLBI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Adjuvants, Immunologic; 0/Angiogenesis Inhibitors; 0/Antibodies, Monoclonal; 0/Antineoplastic Agents; 0/Cancer Vaccines; 0/Cytokines; 0/Enzyme Inhibitors; 0/Oligonucleotides, Antisense |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Prevention of perinatal HIV transmission: a review of novel strategies.
Next Document: Duloxetine: a serotonin-noradrenaline re-uptake inhibitor for the treatment of stress urinary incont...